Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Stock Performance

Minerva Neurosciences stock opened at $1.70 on Tuesday. The firm has a market cap of $11.85 million, a price-to-earnings ratio of -3.85 and a beta of 0.10. Minerva Neurosciences has a 1 year low of $1.42 and a 1 year high of $3.69. The firm’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $2.28.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.49. As a group, equities analysts predict that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Northern Trust Corp grew its stake in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,878 shares of the biopharmaceutical company’s stock after acquiring an additional 13,829 shares during the period. Northern Trust Corp owned 0.53% of Minerva Neurosciences worth $82,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.